SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-139995
Filing Date
2023-05-10
Accepted
2023-05-10 06:54:00
Documents
14
Period of Report
2023-05-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d446953d8k.htm   iXBRL 8-K 31678
2 EX-99.1 d446953dex991.htm EX-99.1 11906
6 GRAPHIC g446953g0510030058693.jpg GRAPHIC 3124
  Complete submission text file 0001193125-23-139995.txt   177085

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cere-20230510.xsd EX-101.SCH 2850
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cere-20230510_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cere-20230510_pre.xml EX-101.PRE 11261
8 EXTRACTED XBRL INSTANCE DOCUMENT d446953d8k_htm.xml XML 3362
Mailing Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141
Business Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141 844-304-2048
Cerevel Therapeutics Holdings, Inc. (Filer) CIK: 0001805387 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39311 | Film No.: 23904258
SIC: 2834 Pharmaceutical Preparations